OrbusNeich Medical Group Holdings Limited (HK:6929)
:6929
Top Page
OrbusNeich Medical Group Holdings Limited
(6929)
Select Model
Select Model
Rating:62Neutral
Price Target:
HK$4.50
▲(1.35% Upside)
Action:ReiteratedDate:11/28/25
The overall score of 62 for HK:6929 is primarily driven by mixed financial performance, with strong profitability and balance sheet health offset by significant cash flow concerns. A reasonable valuation with a low P/E ratio and decent dividend yield provides some support, while bearish technical indicators reflect downward price momentum as a notable risk.
Positive Factors
Revenue Growth
Consistent revenue growth indicates robust market demand and effective sales strategies, supporting long-term business expansion and stability.
Negative Factors
Declining ROE
A declining ROE suggests potential inefficiencies in using equity capital, which could impact investor confidence and long-term return potential.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates robust market demand and effective sales strategies, supporting long-term business expansion and stability.
Read all positive factors
OrbusNeich Medical Group Holdings Limited (6929) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.24B
Dividend Yield2.7%
Average Volume (3M)176.23K
Price to Earnings (P/E)9.1
Beta (1Y)0.57
Revenue Growth11.06%
EPS Growth5.03%
CountryHK
Employees1,331
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.21
Shares Outstanding827,968,300
10 Day Avg. Volume244,250
30 Day Avg. Volume176,233
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)1.00
Price to Sales (P/S)2.41
P/FCF Ratio214.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.30Price Target Upside19.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$197.73M
OrbusNeich Medical Group Holdings Limited Business Overview & Revenue Model
Company Description
OrbusNeich Medical Group Holdings Limited, an investment holding company, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East...
How the Company Makes Money
OrbusNeich generates revenue primarily through the sale of its medical devices and products used in cardiovascular procedures. The company has established a diverse revenue model that includes direct sales to hospitals and healthcare providers, as...
OrbusNeich Medical Group Holdings Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
85
Very Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 168.74M | 164.10M | 153.87M | 136.82M | 116.46M | 88.47M |
| Gross Profit | 114.59M | 114.47M | 106.50M | 92.46M | 81.17M | 58.02M |
| EBITDA | 36.74M | 36.76M | 53.97M | 27.14M | 8.31M | 12.75M |
| Net Income | 40.67M | 39.72M | 45.07M | 18.49M | -4.44M | 7.07M |
Balance Sheet | ||||||
| Total Assets | 445.80M | 431.01M | 410.14M | 351.06M | 268.53M | 103.65M |
| Cash, Cash Equivalents and Short-Term Investments | 248.59M | 248.59M | 256.21M | 247.94M | 175.89M | 15.95M |
| Total Debt | 4.43M | 4.20M | 7.46M | 4.03M | 67.69M | 51.56M |
| Total Liabilities | 35.82M | 36.63M | 40.73M | 28.49M | 85.42M | 68.75M |
| Stockholders Equity | 408.86M | 393.31M | 368.40M | 322.57M | 183.11M | 34.90M |
Cash Flow | ||||||
| Free Cash Flow | 1.76M | 1.84M | 15.55M | 20.10M | 18.36M | 8.91M |
| Operating Cash Flow | 4.90M | 13.11M | 23.03M | 23.43M | 20.50M | 12.67M |
| Investing Cash Flow | 30.67M | 8.65M | -52.31M | -169.32M | -5.22M | -11.24M |
| Financing Cash Flow | -6.56M | -18.96M | 884.00K | 57.44M | 146.31M | -473.00K |
OrbusNeich Medical Group Holdings Limited Technical Analysis
Positive
4.44
Price Trends
3.71
Positive
3.80
Positive
4.09
Negative
Market Momentum
0.04
Negative
66.55
Neutral
73.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6929, the sentiment is Positive. The current price of 4.44 is above the 20-day moving average (MA) of 3.72, above the 50-day MA of 3.71, and above the 200-day MA of 4.09, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 66.55 is Neutral, neither overbought nor oversold. The STOCH value of 73.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6929.
OrbusNeich Medical Group Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$1.66B | 19.04 | 3.68% | 7.46% | 21.39% | -0.57% | |
73 Outperform | HK$8.02B | 20.75 | 11.20% | ― | 14.06% | 3.02% | |
68 Neutral | HK$16.82B | 13.02 | 6.64% | 4.58% | 0.74% | 2.13% | |
66 Neutral | HK$14.14B | 45.44 | 4.98% | ― | ― | ― | |
62 Neutral | HK$3.24B | 9.13 | 10.21% | 2.70% | 11.06% | 5.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6929
OrbusNeich Medical Group Holdings Limited
3.93
0.59
17.66%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.72
-1.78
-32.31%
HK:1358
PW Medtech Group Ltd.
1.13
0.21
22.56%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
37.98
11.18
41.72%
HK:6699
Angelalign Technology Inc.
82.75
33.81
69.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.